An imaging-based analysis of animals treated with ExoPTEN after a spinal cord injury showed more organized spinal cord tissue ...

NORTH CHICAGO, IL, USA I August 21, 2025 I AbbVie (NYSE: ABBV) today announced positive topline results from the second of two pivotal studies of the Phase 3 ...

REYKJAVIK, Iceland and LONDON, UK I August 21, 2025 I Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of ...

SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other ...

SANTA MONICA, CA & PHILADELPHIA, PA, USA I August 21, 2025 I Kite, a Gilead Company (Nasdaq: GILD), today announced that it has entered into a definitive ...

CRANBURY, NJ, USA I, 2025 I Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a ...

CONSHOHOCKEN, PA, USA I August 19, 2025 I Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics ...

Company’s second clinical-stage asset licensed from Mereo Biopharma based on novel insights generated in a mouse model of osteopetrosis - ...

SHANGHAI, China I August 19, 2025 I Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed ...

inMMyCAR is a multi-center Phase 1, open-label, dose-escalation clinical trial designed to assess the safety and preliminary efficacy of a single dose of KLN-1010. The first patient was dosed at Royal ...

A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with ...

SEOUL, South Korea I August 19, 2025 I On August 6, 2025, VASTHERA Co., Ltd. announced that it has received Investigational New Drug (IND) clearance from the ...